Purdue Pharma Announces Risk Strategy for ButransTM

Working with the Food and Drug Administration (FDA), Purdue Pharma L.P. has announced the development of a Risk Evaluation and Mitigation Strategy (REMS) for Butrans(tm) (buprenorphine) Transdermal System.   

The goals of the Butrans REMS Program are:

  1. To inform patients and healthcare professionals about the potential for abuse, misuse, and overdose from, and addiction to Butrans; and
  2. To inform patients and healthcare professionals about the safe use of Butrans

For more idetails visit www.butransrems.com<http://www.butransrems.com> which provides important information for healthcare professionals as well as patients and caregivers.

Printer-Friendly Version

2014 OOA
Member Census

  • FREE IT Services Checkup
  • Chance to win $100 Visa Gift Card
  • Access to other Members-only Benefits

Update Information Now

Contact Us

Call (855) 319-7828 today
to schedule a complimentary practice consultation.

An hour with our team could save you thousands of dollars!

Upcoming Events

 June 2021 
view all >>>